Integra LifeSciences Reports 5.6% Revenue Growth in Q3 2025 Despite Net Loss

Integra LifeSciences Holdings Corporation reported its financial results for the third quarter and the first nine months of 2025, revealing a total revenue of $402.1 million for the three months ended September 30, 2025, an increase of 5.6% from $380.8 million in the same period of 2024. For the nine months, revenue reached $1.2 billion, up from $1.17 billion year-over-year. Despite the revenue growth, the company recorded a net loss of $5.4 million for the third quarter, an improvement from a loss of $10.7 million in the prior year. However, the nine-month net loss widened significantly to $514.8 million, primarily due to a goodwill impairment charge of $511.4 million recognized in the second quarter.

The company’s operational performance was impacted by quality and operational issues, particularly in its Tissue Technologies segment, which saw a revenue decline of 5% to $323.1 million for the nine months ended September 30, 2025. This decline was attributed to challenges with Medihoney products and decreased private label revenues. Conversely, the Codman Specialty Surgical segment experienced a revenue increase of 6% to $877.2 million, bolstered by the acquisition of Acclarent and recovery in certain product lines. Gross margin for the nine months decreased to 50.9% from 54.2%, reflecting the adverse effects of operational challenges and increased manufacturing costs.

Strategically, Integra has been active in expanding its product offerings and geographic reach. The company completed the acquisition of Acclarent in April 2024, enhancing its position in the ENT market. Additionally, Integra launched new products, including the Durepair Dural Regeneration Matrix, and expanded its international presence, particularly in Southeast Asia and India. The company is also transitioning manufacturing from its Boston facility to a new site in Braintree, Massachusetts, expected to be operational in 2026.

As of September 30, 2025, Integra reported total assets of $3.65 billion, down from $4.04 billion at the end of 2024, largely due to the impairment of goodwill. The company’s cash and cash equivalents stood at $232.2 million, with short-term investments increasing to $35.7 million. The company’s working capital improved significantly to $779.5 million, driven by the repayment of its 2025 Notes. Looking ahead, Integra anticipates continued challenges from quality issues and macroeconomic factors, including tariffs and inflation, which may impact its operations and financial performance. The company remains focused on executing its growth strategy while managing its operational and financial risks.